nodes	percent_of_prediction	percent_of_DWPC	metapath
Eletriptan—migraine—Prednisone—hematologic cancer	0.33	1	CpDpCtD
Eletriptan—ABCB1—hematologic cancer	0.0525	1	CbGaD
Eletriptan—CYP2A6—Methoxsalen—hematologic cancer	0.0194	0.0497	CbGbCtD
Eletriptan—PTGS1—Bortezomib—hematologic cancer	0.0158	0.0404	CbGbCtD
Eletriptan—CYP2A6—Ifosfamide—hematologic cancer	0.0142	0.0363	CbGbCtD
Eletriptan—PTGS1—Thalidomide—hematologic cancer	0.0138	0.0352	CbGbCtD
Eletriptan—PTGS1—Ifosfamide—hematologic cancer	0.0121	0.031	CbGbCtD
Eletriptan—PTGS1—Imatinib—hematologic cancer	0.0116	0.0296	CbGbCtD
Eletriptan—CYP2C9—Bexarotene—hematologic cancer	0.0104	0.0265	CbGbCtD
Eletriptan—ABCB1—Lenalidomide—hematologic cancer	0.0101	0.0258	CbGbCtD
Eletriptan—CYP2A6—Prednisolone—hematologic cancer	0.00945	0.0242	CbGbCtD
Eletriptan—CYP2D6—Lomustine—hematologic cancer	0.00882	0.0226	CbGbCtD
Eletriptan—CYP2C9—Idarubicin—hematologic cancer	0.00859	0.022	CbGbCtD
Eletriptan—CYP2D6—Idarubicin—hematologic cancer	0.00786	0.0201	CbGbCtD
Eletriptan—CYP2C19—Bortezomib—hematologic cancer	0.00765	0.0196	CbGbCtD
Eletriptan—CYP2D6—Hydroxyurea—hematologic cancer	0.00668	0.0171	CbGbCtD
Eletriptan—CYP2C19—Thalidomide—hematologic cancer	0.00666	0.017	CbGbCtD
Eletriptan—CYP2C9—Bortezomib—hematologic cancer	0.00636	0.0163	CbGbCtD
Eletriptan—CYP2C19—Teniposide—hematologic cancer	0.00635	0.0163	CbGbCtD
Eletriptan—CYP3A4—Bexarotene—hematologic cancer	0.00603	0.0154	CbGbCtD
Eletriptan—ABCB1—Daunorubicin—hematologic cancer	0.0059	0.0151	CbGbCtD
Eletriptan—CYP2C19—Ifosfamide—hematologic cancer	0.00586	0.015	CbGbCtD
Eletriptan—CYP2D6—Bortezomib—hematologic cancer	0.00581	0.0149	CbGbCtD
Eletriptan—PTGS1—Etoposide—hematologic cancer	0.00579	0.0148	CbGbCtD
Eletriptan—ABCB1—Alitretinoin—hematologic cancer	0.00578	0.0148	CbGbCtD
Eletriptan—CYP3A4—Busulfan—hematologic cancer	0.00561	0.0143	CbGbCtD
Eletriptan—CYP3A4—Lomustine—hematologic cancer	0.00561	0.0143	CbGbCtD
Eletriptan—CYP2C19—Imatinib—hematologic cancer	0.0056	0.0143	CbGbCtD
Eletriptan—CYP2A6—Dexamethasone—hematologic cancer	0.00557	0.0143	CbGbCtD
Eletriptan—CYP2C9—Thalidomide—hematologic cancer	0.00554	0.0142	CbGbCtD
Eletriptan—CYP2C9—Teniposide—hematologic cancer	0.00528	0.0135	CbGbCtD
Eletriptan—CYP3A4—Thiotepa—hematologic cancer	0.005	0.0128	CbGbCtD
Eletriptan—CYP2C9—Ifosfamide—hematologic cancer	0.00488	0.0125	CbGbCtD
Eletriptan—CYP2C9—Imatinib—hematologic cancer	0.00466	0.0119	CbGbCtD
Eletriptan—ABCB1—Imatinib—hematologic cancer	0.00452	0.0116	CbGbCtD
Eletriptan—CYP2D6—Imatinib—hematologic cancer	0.00426	0.0109	CbGbCtD
Eletriptan—CYP2C9—Nilotinib—hematologic cancer	0.00423	0.0108	CbGbCtD
Eletriptan—ABCB1—Nilotinib—hematologic cancer	0.00411	0.0105	CbGbCtD
Eletriptan—ABCB1—Vinorelbine—hematologic cancer	0.00407	0.0104	CbGbCtD
Eletriptan—CYP3A4—Methoxsalen—hematologic cancer	0.00389	0.00994	CbGbCtD
Eletriptan—CYP2D6—Nilotinib—hematologic cancer	0.00387	0.0099	CbGbCtD
Eletriptan—CYP2D6—Vinorelbine—hematologic cancer	0.00384	0.00982	CbGbCtD
Eletriptan—CYP3A4—Bortezomib—hematologic cancer	0.0037	0.00946	CbGbCtD
Eletriptan—CYP2C19—Prednisone—hematologic cancer	0.00369	0.00945	CbGbCtD
Eletriptan—ABCB1—Dasatinib—hematologic cancer	0.00363	0.00929	CbGbCtD
Eletriptan—ABCB1—Mitoxantrone—hematologic cancer	0.00359	0.00918	CbGbCtD
Eletriptan—CYP3A4—Daunorubicin—hematologic cancer	0.00354	0.00905	CbGbCtD
Eletriptan—ABCB1—Betamethasone—hematologic cancer	0.0032	0.00818	CbGbCtD
Eletriptan—ABCB1—Gemcitabine—hematologic cancer	0.00317	0.00811	CbGbCtD
Eletriptan—ABCB1—Prednisolone—hematologic cancer	0.00315	0.00807	CbGbCtD
Eletriptan—CYP3A4—Cytarabine—hematologic cancer	0.00312	0.00798	CbGbCtD
Eletriptan—CYP3A4—Teniposide—hematologic cancer	0.00307	0.00786	CbGbCtD
Eletriptan—ABCB1—Prednisone—hematologic cancer	0.00298	0.00762	CbGbCtD
Eletriptan—CYP3A4—Ifosfamide—hematologic cancer	0.00284	0.00725	CbGbCtD
Eletriptan—ABCB1—Irinotecan—hematologic cancer	0.00282	0.00722	CbGbCtD
Eletriptan—CYP3A4—Imatinib—hematologic cancer	0.00271	0.00693	CbGbCtD
Eletriptan—CYP3A4—Ruxolitinib—hematologic cancer	0.00255	0.00653	CbGbCtD
Eletriptan—ABCB1—Vinblastine—hematologic cancer	0.00251	0.00642	CbGbCtD
Eletriptan—ABCB1—Vincristine—hematologic cancer	0.00247	0.00631	CbGbCtD
Eletriptan—CYP3A4—Nilotinib—hematologic cancer	0.00246	0.0063	CbGbCtD
Eletriptan—CYP3A4—Vinorelbine—hematologic cancer	0.00244	0.00625	CbGbCtD
Eletriptan—CYP2C9—Cisplatin—hematologic cancer	0.00237	0.00607	CbGbCtD
Eletriptan—CYP2D6—Vinblastine—hematologic cancer	0.00237	0.00605	CbGbCtD
Eletriptan—CYP2C19—Dexamethasone—hematologic cancer	0.0023	0.0059	CbGbCtD
Eletriptan—ABCB1—Cisplatin—hematologic cancer	0.0023	0.00589	CbGbCtD
Eletriptan—ABCB1—Etoposide—hematologic cancer	0.00226	0.00579	CbGbCtD
Eletriptan—CYP3A4—Triamcinolone—hematologic cancer	0.00223	0.00571	CbGbCtD
Eletriptan—CYP3A4—Dasatinib—hematologic cancer	0.00218	0.00557	CbGbCtD
Eletriptan—CYP3A4—Mitoxantrone—hematologic cancer	0.00215	0.0055	CbGbCtD
Eletriptan—CYP2C9—Dexamethasone—hematologic cancer	0.00192	0.0049	CbGbCtD
Eletriptan—CYP3A4—Betamethasone—hematologic cancer	0.00192	0.0049	CbGbCtD
Eletriptan—CYP3A4—Prednisolone—hematologic cancer	0.00189	0.00484	CbGbCtD
Eletriptan—ABCB1—Dexamethasone—hematologic cancer	0.00186	0.00476	CbGbCtD
Eletriptan—CYP3A4—Prednisone—hematologic cancer	0.00178	0.00457	CbGbCtD
Eletriptan—CYP2D6—Dexamethasone—hematologic cancer	0.00175	0.00448	CbGbCtD
Eletriptan—CYP3A4—Irinotecan—hematologic cancer	0.00169	0.00433	CbGbCtD
Eletriptan—ABCB1—Doxorubicin—hematologic cancer	0.00154	0.00395	CbGbCtD
Eletriptan—CYP3A4—Vinblastine—hematologic cancer	0.0015	0.00385	CbGbCtD
Eletriptan—ABCB1—Methotrexate—hematologic cancer	0.00149	0.00382	CbGbCtD
Eletriptan—CYP3A4—Vincristine—hematologic cancer	0.00148	0.00378	CbGbCtD
Eletriptan—CYP2D6—Doxorubicin—hematologic cancer	0.00145	0.00372	CbGbCtD
Eletriptan—CYP3A4—Etoposide—hematologic cancer	0.00135	0.00347	CbGbCtD
Eletriptan—CYP3A4—Dexamethasone—hematologic cancer	0.00111	0.00285	CbGbCtD
Eletriptan—CYP3A4—Doxorubicin—hematologic cancer	0.000924	0.00236	CbGbCtD
Eletriptan—HTR1A—hematopoietic system—hematologic cancer	4.36e-05	0.0631	CbGeAlD
Eletriptan—HTR7—hematopoietic system—hematologic cancer	4.16e-05	0.0603	CbGeAlD
Eletriptan—CYP2C19—hematopoietic system—hematologic cancer	4.07e-05	0.0589	CbGeAlD
Eletriptan—CYP2A6—lung—hematologic cancer	3.67e-05	0.0532	CbGeAlD
Eletriptan—HTR2B—blood—hematologic cancer	3.22e-05	0.0467	CbGeAlD
Eletriptan—HTR7—gonad—hematologic cancer	3.17e-05	0.0459	CbGeAlD
Eletriptan—CYP2C9—hematopoietic system—hematologic cancer	3.15e-05	0.0457	CbGeAlD
Eletriptan—PTGS1—hematopoietic system—hematologic cancer	2.88e-05	0.0417	CbGeAlD
Eletriptan—HTR2B—lung—hematologic cancer	2.82e-05	0.0409	CbGeAlD
Eletriptan—HTR7—blood—hematologic cancer	2.76e-05	0.04	CbGeAlD
Eletriptan—CYP2C19—blood—hematologic cancer	2.69e-05	0.039	CbGeAlD
Eletriptan—HTR7—lung—hematologic cancer	2.42e-05	0.035	CbGeAlD
Eletriptan—CYP3A4—hematopoietic system—hematologic cancer	2.4e-05	0.0348	CbGeAlD
Eletriptan—CYP2D6—hematopoietic system—hematologic cancer	2.37e-05	0.0343	CbGeAlD
Eletriptan—HTR7—testis—hematologic cancer	2.28e-05	0.0331	CbGeAlD
Eletriptan—CYP2C9—blood—hematologic cancer	2.09e-05	0.0303	CbGeAlD
Eletriptan—HTR2B—lymph node—hematologic cancer	1.93e-05	0.028	CbGeAlD
Eletriptan—PTGS1—blood—hematologic cancer	1.91e-05	0.0276	CbGeAlD
Eletriptan—ABCB1—hematopoietic system—hematologic cancer	1.7e-05	0.0247	CbGeAlD
Eletriptan—PTGS1—lung—hematologic cancer	1.67e-05	0.0242	CbGeAlD
Eletriptan—CYP3A4—blood—hematologic cancer	1.59e-05	0.0231	CbGeAlD
Eletriptan—PTGS1—testis—hematologic cancer	1.58e-05	0.0229	CbGeAlD
Eletriptan—CYP2D6—blood—hematologic cancer	1.57e-05	0.0227	CbGeAlD
Eletriptan—Pain—Betamethasone—hematologic cancer	1.44e-05	8.21e-05	CcSEcCtD
Eletriptan—Visual impairment—Doxorubicin—hematologic cancer	1.44e-05	8.21e-05	CcSEcCtD
Eletriptan—Nervous system disorder—Prednisone—hematologic cancer	1.44e-05	8.2e-05	CcSEcCtD
Eletriptan—Tachycardia—Prednisone—hematologic cancer	1.43e-05	8.16e-05	CcSEcCtD
Eletriptan—Alopecia—Epirubicin—hematologic cancer	1.43e-05	8.13e-05	CcSEcCtD
Eletriptan—Skin disorder—Prednisone—hematologic cancer	1.42e-05	8.12e-05	CcSEcCtD
Eletriptan—Nausea—Gemcitabine—hematologic cancer	1.42e-05	8.12e-05	CcSEcCtD
Eletriptan—Vomiting—Cisplatin—hematologic cancer	1.42e-05	8.1e-05	CcSEcCtD
Eletriptan—Hyperhidrosis—Prednisone—hematologic cancer	1.42e-05	8.08e-05	CcSEcCtD
Eletriptan—Rash—Cisplatin—hematologic cancer	1.41e-05	8.03e-05	CcSEcCtD
Eletriptan—Dermatitis—Cisplatin—hematologic cancer	1.41e-05	8.02e-05	CcSEcCtD
Eletriptan—Diarrhoea—Etoposide—hematologic cancer	1.4e-05	7.98e-05	CcSEcCtD
Eletriptan—Anorexia—Prednisone—hematologic cancer	1.4e-05	7.97e-05	CcSEcCtD
Eletriptan—Ill-defined disorder—Methotrexate—hematologic cancer	1.39e-05	7.95e-05	CcSEcCtD
Eletriptan—Tinnitus—Doxorubicin—hematologic cancer	1.39e-05	7.94e-05	CcSEcCtD
Eletriptan—Anaemia—Methotrexate—hematologic cancer	1.39e-05	7.91e-05	CcSEcCtD
Eletriptan—Feeling abnormal—Dexamethasone—hematologic cancer	1.39e-05	7.91e-05	CcSEcCtD
Eletriptan—Feeling abnormal—Betamethasone—hematologic cancer	1.39e-05	7.91e-05	CcSEcCtD
Eletriptan—Flushing—Doxorubicin—hematologic cancer	1.38e-05	7.91e-05	CcSEcCtD
Eletriptan—Flatulence—Epirubicin—hematologic cancer	1.38e-05	7.9e-05	CcSEcCtD
Eletriptan—Tension—Epirubicin—hematologic cancer	1.38e-05	7.86e-05	CcSEcCtD
Eletriptan—Gastrointestinal pain—Betamethasone—hematologic cancer	1.38e-05	7.85e-05	CcSEcCtD
Eletriptan—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.38e-05	7.85e-05	CcSEcCtD
Eletriptan—Dysgeusia—Epirubicin—hematologic cancer	1.37e-05	7.85e-05	CcSEcCtD
Eletriptan—Hypersensitivity—Triamcinolone—hematologic cancer	1.37e-05	7.8e-05	CcSEcCtD
Eletriptan—Nervousness—Epirubicin—hematologic cancer	1.36e-05	7.78e-05	CcSEcCtD
Eletriptan—Back pain—Epirubicin—hematologic cancer	1.36e-05	7.75e-05	CcSEcCtD
Eletriptan—Malaise—Methotrexate—hematologic cancer	1.35e-05	7.72e-05	CcSEcCtD
Eletriptan—Dizziness—Etoposide—hematologic cancer	1.35e-05	7.72e-05	CcSEcCtD
Eletriptan—Muscle spasms—Epirubicin—hematologic cancer	1.35e-05	7.7e-05	CcSEcCtD
Eletriptan—Immune system disorder—Doxorubicin—hematologic cancer	1.35e-05	7.69e-05	CcSEcCtD
Eletriptan—Vertigo—Methotrexate—hematologic cancer	1.35e-05	7.69e-05	CcSEcCtD
Eletriptan—Leukopenia—Methotrexate—hematologic cancer	1.34e-05	7.67e-05	CcSEcCtD
Eletriptan—Chills—Doxorubicin—hematologic cancer	1.34e-05	7.64e-05	CcSEcCtD
Eletriptan—Urticaria—Dexamethasone—hematologic cancer	1.34e-05	7.63e-05	CcSEcCtD
Eletriptan—Urticaria—Betamethasone—hematologic cancer	1.34e-05	7.63e-05	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.33e-05	7.62e-05	CcSEcCtD
Eletriptan—Dizziness—Prednisolone—hematologic cancer	1.33e-05	7.61e-05	CcSEcCtD
Eletriptan—Arrhythmia—Doxorubicin—hematologic cancer	1.33e-05	7.61e-05	CcSEcCtD
Eletriptan—Asthenia—Triamcinolone—hematologic cancer	1.33e-05	7.59e-05	CcSEcCtD
Eletriptan—Body temperature increased—Betamethasone—hematologic cancer	1.33e-05	7.59e-05	CcSEcCtD
Eletriptan—Body temperature increased—Dexamethasone—hematologic cancer	1.33e-05	7.59e-05	CcSEcCtD
Eletriptan—Abdominal pain—Dexamethasone—hematologic cancer	1.33e-05	7.59e-05	CcSEcCtD
Eletriptan—Abdominal pain—Betamethasone—hematologic cancer	1.33e-05	7.59e-05	CcSEcCtD
Eletriptan—Nausea—Cisplatin—hematologic cancer	1.33e-05	7.56e-05	CcSEcCtD
Eletriptan—Insomnia—Prednisone—hematologic cancer	1.33e-05	7.56e-05	CcSEcCtD
Eletriptan—Alopecia—Doxorubicin—hematologic cancer	1.32e-05	7.53e-05	CcSEcCtD
Eletriptan—Paraesthesia—Prednisone—hematologic cancer	1.32e-05	7.51e-05	CcSEcCtD
Eletriptan—Pruritus—Triamcinolone—hematologic cancer	1.31e-05	7.49e-05	CcSEcCtD
Eletriptan—Cough—Methotrexate—hematologic cancer	1.31e-05	7.47e-05	CcSEcCtD
Eletriptan—Ill-defined disorder—Epirubicin—hematologic cancer	1.3e-05	7.44e-05	CcSEcCtD
Eletriptan—Convulsion—Methotrexate—hematologic cancer	1.3e-05	7.42e-05	CcSEcCtD
Eletriptan—Vomiting—Etoposide—hematologic cancer	1.3e-05	7.42e-05	CcSEcCtD
Eletriptan—Anaemia—Epirubicin—hematologic cancer	1.3e-05	7.41e-05	CcSEcCtD
Eletriptan—CYP2D6—testis—hematologic cancer	1.3e-05	0.0188	CbGeAlD
Eletriptan—ABCB1—gonad—hematologic cancer	1.29e-05	0.0187	CbGeAlD
Eletriptan—Agitation—Epirubicin—hematologic cancer	1.29e-05	7.36e-05	CcSEcCtD
Eletriptan—Dyspepsia—Prednisone—hematologic cancer	1.29e-05	7.36e-05	CcSEcCtD
Eletriptan—Rash—Etoposide—hematologic cancer	1.29e-05	7.36e-05	CcSEcCtD
Eletriptan—Dermatitis—Etoposide—hematologic cancer	1.29e-05	7.35e-05	CcSEcCtD
Eletriptan—Headache—Etoposide—hematologic cancer	1.28e-05	7.31e-05	CcSEcCtD
Eletriptan—Flatulence—Doxorubicin—hematologic cancer	1.28e-05	7.31e-05	CcSEcCtD
Eletriptan—Myalgia—Methotrexate—hematologic cancer	1.28e-05	7.29e-05	CcSEcCtD
Eletriptan—Arthralgia—Methotrexate—hematologic cancer	1.28e-05	7.29e-05	CcSEcCtD
Eletriptan—Tension—Doxorubicin—hematologic cancer	1.27e-05	7.28e-05	CcSEcCtD
Eletriptan—Decreased appetite—Prednisone—hematologic cancer	1.27e-05	7.27e-05	CcSEcCtD
Eletriptan—Dysgeusia—Doxorubicin—hematologic cancer	1.27e-05	7.26e-05	CcSEcCtD
Eletriptan—Rash—Prednisolone—hematologic cancer	1.27e-05	7.26e-05	CcSEcCtD
Eletriptan—Dermatitis—Prednisolone—hematologic cancer	1.27e-05	7.25e-05	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.27e-05	7.24e-05	CcSEcCtD
Eletriptan—Malaise—Epirubicin—hematologic cancer	1.27e-05	7.23e-05	CcSEcCtD
Eletriptan—Fatigue—Prednisone—hematologic cancer	1.26e-05	7.21e-05	CcSEcCtD
Eletriptan—Headache—Prednisolone—hematologic cancer	1.26e-05	7.21e-05	CcSEcCtD
Eletriptan—Discomfort—Methotrexate—hematologic cancer	1.26e-05	7.2e-05	CcSEcCtD
Eletriptan—Nervousness—Doxorubicin—hematologic cancer	1.26e-05	7.2e-05	CcSEcCtD
Eletriptan—Vertigo—Epirubicin—hematologic cancer	1.26e-05	7.2e-05	CcSEcCtD
Eletriptan—Syncope—Epirubicin—hematologic cancer	1.26e-05	7.19e-05	CcSEcCtD
Eletriptan—Leukopenia—Epirubicin—hematologic cancer	1.26e-05	7.17e-05	CcSEcCtD
Eletriptan—Back pain—Doxorubicin—hematologic cancer	1.26e-05	7.17e-05	CcSEcCtD
Eletriptan—Constipation—Prednisone—hematologic cancer	1.25e-05	7.15e-05	CcSEcCtD
Eletriptan—Muscle spasms—Doxorubicin—hematologic cancer	1.25e-05	7.13e-05	CcSEcCtD
Eletriptan—Palpitations—Epirubicin—hematologic cancer	1.24e-05	7.08e-05	CcSEcCtD
Eletriptan—Confusional state—Methotrexate—hematologic cancer	1.23e-05	7.05e-05	CcSEcCtD
Eletriptan—Loss of consciousness—Epirubicin—hematologic cancer	1.23e-05	7.04e-05	CcSEcCtD
Eletriptan—Dizziness—Triamcinolone—hematologic cancer	1.23e-05	7e-05	CcSEcCtD
Eletriptan—Cough—Epirubicin—hematologic cancer	1.23e-05	6.99e-05	CcSEcCtD
Eletriptan—Convulsion—Epirubicin—hematologic cancer	1.22e-05	6.94e-05	CcSEcCtD
Eletriptan—Nausea—Etoposide—hematologic cancer	1.21e-05	6.93e-05	CcSEcCtD
Eletriptan—Hypertension—Epirubicin—hematologic cancer	1.21e-05	6.92e-05	CcSEcCtD
Eletriptan—Feeling abnormal—Prednisone—hematologic cancer	1.21e-05	6.89e-05	CcSEcCtD
Eletriptan—Asthenia—Betamethasone—hematologic cancer	1.21e-05	6.89e-05	CcSEcCtD
Eletriptan—Asthenia—Dexamethasone—hematologic cancer	1.21e-05	6.89e-05	CcSEcCtD
Eletriptan—Ill-defined disorder—Doxorubicin—hematologic cancer	1.21e-05	6.88e-05	CcSEcCtD
Eletriptan—Nervous system disorder—Methotrexate—hematologic cancer	1.2e-05	6.85e-05	CcSEcCtD
Eletriptan—Anaemia—Doxorubicin—hematologic cancer	1.2e-05	6.85e-05	CcSEcCtD
Eletriptan—Gastrointestinal pain—Prednisone—hematologic cancer	1.2e-05	6.84e-05	CcSEcCtD
Eletriptan—Nausea—Prednisolone—hematologic cancer	1.2e-05	6.84e-05	CcSEcCtD
Eletriptan—Arthralgia—Epirubicin—hematologic cancer	1.2e-05	6.82e-05	CcSEcCtD
Eletriptan—Myalgia—Epirubicin—hematologic cancer	1.2e-05	6.82e-05	CcSEcCtD
Eletriptan—Agitation—Doxorubicin—hematologic cancer	1.19e-05	6.81e-05	CcSEcCtD
Eletriptan—Anxiety—Epirubicin—hematologic cancer	1.19e-05	6.8e-05	CcSEcCtD
Eletriptan—Pruritus—Betamethasone—hematologic cancer	1.19e-05	6.79e-05	CcSEcCtD
Eletriptan—Pruritus—Dexamethasone—hematologic cancer	1.19e-05	6.79e-05	CcSEcCtD
Eletriptan—Skin disorder—Methotrexate—hematologic cancer	1.19e-05	6.79e-05	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.19e-05	6.78e-05	CcSEcCtD
Eletriptan—Hyperhidrosis—Methotrexate—hematologic cancer	1.18e-05	6.76e-05	CcSEcCtD
Eletriptan—Discomfort—Epirubicin—hematologic cancer	1.18e-05	6.74e-05	CcSEcCtD
Eletriptan—Vomiting—Triamcinolone—hematologic cancer	1.18e-05	6.73e-05	CcSEcCtD
Eletriptan—Malaise—Doxorubicin—hematologic cancer	1.17e-05	6.69e-05	CcSEcCtD
Eletriptan—Rash—Triamcinolone—hematologic cancer	1.17e-05	6.67e-05	CcSEcCtD
Eletriptan—Dry mouth—Epirubicin—hematologic cancer	1.17e-05	6.67e-05	CcSEcCtD
Eletriptan—Dermatitis—Triamcinolone—hematologic cancer	1.17e-05	6.67e-05	CcSEcCtD
Eletriptan—Vertigo—Doxorubicin—hematologic cancer	1.17e-05	6.66e-05	CcSEcCtD
Eletriptan—Anorexia—Methotrexate—hematologic cancer	1.17e-05	6.66e-05	CcSEcCtD
Eletriptan—Syncope—Doxorubicin—hematologic cancer	1.16e-05	6.65e-05	CcSEcCtD
Eletriptan—Urticaria—Prednisone—hematologic cancer	1.16e-05	6.64e-05	CcSEcCtD
Eletriptan—Leukopenia—Doxorubicin—hematologic cancer	1.16e-05	6.64e-05	CcSEcCtD
Eletriptan—Headache—Triamcinolone—hematologic cancer	1.16e-05	6.63e-05	CcSEcCtD
Eletriptan—Abdominal pain—Prednisone—hematologic cancer	1.16e-05	6.61e-05	CcSEcCtD
Eletriptan—Body temperature increased—Prednisone—hematologic cancer	1.16e-05	6.61e-05	CcSEcCtD
Eletriptan—Confusional state—Epirubicin—hematologic cancer	1.16e-05	6.59e-05	CcSEcCtD
Eletriptan—Diarrhoea—Dexamethasone—hematologic cancer	1.15e-05	6.57e-05	CcSEcCtD
Eletriptan—Diarrhoea—Betamethasone—hematologic cancer	1.15e-05	6.57e-05	CcSEcCtD
Eletriptan—Palpitations—Doxorubicin—hematologic cancer	1.15e-05	6.55e-05	CcSEcCtD
Eletriptan—Oedema—Epirubicin—hematologic cancer	1.15e-05	6.54e-05	CcSEcCtD
Eletriptan—Hypotension—Methotrexate—hematologic cancer	1.14e-05	6.53e-05	CcSEcCtD
Eletriptan—PTGS1—lymph node—hematologic cancer	1.14e-05	0.0166	CbGeAlD
Eletriptan—Loss of consciousness—Doxorubicin—hematologic cancer	1.14e-05	6.52e-05	CcSEcCtD
Eletriptan—Cough—Doxorubicin—hematologic cancer	1.13e-05	6.47e-05	CcSEcCtD
Eletriptan—Shock—Epirubicin—hematologic cancer	1.13e-05	6.43e-05	CcSEcCtD
Eletriptan—ABCB1—blood—hematologic cancer	1.13e-05	0.0163	CbGeAlD
Eletriptan—Convulsion—Doxorubicin—hematologic cancer	1.13e-05	6.42e-05	CcSEcCtD
Eletriptan—Nervous system disorder—Epirubicin—hematologic cancer	1.12e-05	6.41e-05	CcSEcCtD
Eletriptan—Hypertension—Doxorubicin—hematologic cancer	1.12e-05	6.4e-05	CcSEcCtD
Eletriptan—Tachycardia—Epirubicin—hematologic cancer	1.12e-05	6.38e-05	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.12e-05	6.37e-05	CcSEcCtD
Eletriptan—Skin disorder—Epirubicin—hematologic cancer	1.11e-05	6.35e-05	CcSEcCtD
Eletriptan—Dizziness—Betamethasone—hematologic cancer	1.11e-05	6.35e-05	CcSEcCtD
Eletriptan—Dizziness—Dexamethasone—hematologic cancer	1.11e-05	6.35e-05	CcSEcCtD
Eletriptan—Hyperhidrosis—Epirubicin—hematologic cancer	1.11e-05	6.32e-05	CcSEcCtD
Eletriptan—Insomnia—Methotrexate—hematologic cancer	1.11e-05	6.32e-05	CcSEcCtD
Eletriptan—Arthralgia—Doxorubicin—hematologic cancer	1.11e-05	6.31e-05	CcSEcCtD
Eletriptan—Myalgia—Doxorubicin—hematologic cancer	1.11e-05	6.31e-05	CcSEcCtD
Eletriptan—Anxiety—Doxorubicin—hematologic cancer	1.1e-05	6.29e-05	CcSEcCtD
Eletriptan—Nausea—Triamcinolone—hematologic cancer	1.1e-05	6.29e-05	CcSEcCtD
Eletriptan—Paraesthesia—Methotrexate—hematologic cancer	1.1e-05	6.28e-05	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.1e-05	6.27e-05	CcSEcCtD
Eletriptan—Discomfort—Doxorubicin—hematologic cancer	1.09e-05	6.24e-05	CcSEcCtD
Eletriptan—Anorexia—Epirubicin—hematologic cancer	1.09e-05	6.23e-05	CcSEcCtD
Eletriptan—Dyspnoea—Methotrexate—hematologic cancer	1.09e-05	6.23e-05	CcSEcCtD
Eletriptan—ABCB1—bone marrow—hematologic cancer	1.09e-05	0.0158	CbGeAlD
Eletriptan—Somnolence—Methotrexate—hematologic cancer	1.09e-05	6.21e-05	CcSEcCtD
Eletriptan—Dry mouth—Doxorubicin—hematologic cancer	1.08e-05	6.17e-05	CcSEcCtD
Eletriptan—Hypersensitivity—Prednisone—hematologic cancer	1.08e-05	6.16e-05	CcSEcCtD
Eletriptan—Dyspepsia—Methotrexate—hematologic cancer	1.08e-05	6.15e-05	CcSEcCtD
Eletriptan—Hypotension—Epirubicin—hematologic cancer	1.07e-05	6.11e-05	CcSEcCtD
Eletriptan—Vomiting—Betamethasone—hematologic cancer	1.07e-05	6.11e-05	CcSEcCtD
Eletriptan—Vomiting—Dexamethasone—hematologic cancer	1.07e-05	6.11e-05	CcSEcCtD
Eletriptan—Confusional state—Doxorubicin—hematologic cancer	1.07e-05	6.1e-05	CcSEcCtD
Eletriptan—Decreased appetite—Methotrexate—hematologic cancer	1.06e-05	6.08e-05	CcSEcCtD
Eletriptan—Rash—Dexamethasone—hematologic cancer	1.06e-05	6.05e-05	CcSEcCtD
Eletriptan—Rash—Betamethasone—hematologic cancer	1.06e-05	6.05e-05	CcSEcCtD
Eletriptan—Oedema—Doxorubicin—hematologic cancer	1.06e-05	6.05e-05	CcSEcCtD
Eletriptan—Dermatitis—Betamethasone—hematologic cancer	1.06e-05	6.05e-05	CcSEcCtD
Eletriptan—Dermatitis—Dexamethasone—hematologic cancer	1.06e-05	6.05e-05	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.06e-05	6.03e-05	CcSEcCtD
Eletriptan—Fatigue—Methotrexate—hematologic cancer	1.06e-05	6.03e-05	CcSEcCtD
Eletriptan—Headache—Dexamethasone—hematologic cancer	1.05e-05	6.02e-05	CcSEcCtD
Eletriptan—Headache—Betamethasone—hematologic cancer	1.05e-05	6.02e-05	CcSEcCtD
Eletriptan—Asthenia—Prednisone—hematologic cancer	1.05e-05	6e-05	CcSEcCtD
Eletriptan—Pain—Methotrexate—hematologic cancer	1.05e-05	5.98e-05	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.04e-05	5.96e-05	CcSEcCtD
Eletriptan—Shock—Doxorubicin—hematologic cancer	1.04e-05	5.95e-05	CcSEcCtD
Eletriptan—Nervous system disorder—Doxorubicin—hematologic cancer	1.04e-05	5.93e-05	CcSEcCtD
Eletriptan—Pruritus—Prednisone—hematologic cancer	1.04e-05	5.92e-05	CcSEcCtD
Eletriptan—Insomnia—Epirubicin—hematologic cancer	1.04e-05	5.92e-05	CcSEcCtD
Eletriptan—Tachycardia—Doxorubicin—hematologic cancer	1.03e-05	5.91e-05	CcSEcCtD
Eletriptan—Sumatriptan—ABCG2—hematologic cancer	1.03e-05	0.706	CrCbGaD
Eletriptan—Skin disorder—Doxorubicin—hematologic cancer	1.03e-05	5.88e-05	CcSEcCtD
Eletriptan—Paraesthesia—Epirubicin—hematologic cancer	1.03e-05	5.87e-05	CcSEcCtD
Eletriptan—Hyperhidrosis—Doxorubicin—hematologic cancer	1.02e-05	5.85e-05	CcSEcCtD
Eletriptan—Dyspnoea—Epirubicin—hematologic cancer	1.02e-05	5.83e-05	CcSEcCtD
Eletriptan—Somnolence—Epirubicin—hematologic cancer	1.02e-05	5.81e-05	CcSEcCtD
Eletriptan—Anorexia—Doxorubicin—hematologic cancer	1.01e-05	5.77e-05	CcSEcCtD
Eletriptan—Feeling abnormal—Methotrexate—hematologic cancer	1.01e-05	5.76e-05	CcSEcCtD
Eletriptan—Dyspepsia—Epirubicin—hematologic cancer	1.01e-05	5.76e-05	CcSEcCtD
Eletriptan—Diarrhoea—Prednisone—hematologic cancer	1e-05	5.72e-05	CcSEcCtD
Eletriptan—Gastrointestinal pain—Methotrexate—hematologic cancer	1e-05	5.71e-05	CcSEcCtD
Eletriptan—Nausea—Dexamethasone—hematologic cancer	9.99e-06	5.7e-05	CcSEcCtD
Eletriptan—Nausea—Betamethasone—hematologic cancer	9.99e-06	5.7e-05	CcSEcCtD
Eletriptan—Decreased appetite—Epirubicin—hematologic cancer	9.96e-06	5.69e-05	CcSEcCtD
Eletriptan—Hypotension—Doxorubicin—hematologic cancer	9.91e-06	5.65e-05	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Epirubicin—hematologic cancer	9.89e-06	5.65e-05	CcSEcCtD
Eletriptan—ABCB1—lung—hematologic cancer	9.88e-06	0.0143	CbGeAlD
Eletriptan—Fatigue—Epirubicin—hematologic cancer	9.88e-06	5.64e-05	CcSEcCtD
Eletriptan—Pain—Epirubicin—hematologic cancer	9.8e-06	5.59e-05	CcSEcCtD
Eletriptan—Constipation—Epirubicin—hematologic cancer	9.8e-06	5.59e-05	CcSEcCtD
Eletriptan—Urticaria—Methotrexate—hematologic cancer	9.73e-06	5.55e-05	CcSEcCtD
Eletriptan—Dizziness—Prednisone—hematologic cancer	9.69e-06	5.53e-05	CcSEcCtD
Eletriptan—Abdominal pain—Methotrexate—hematologic cancer	9.68e-06	5.52e-05	CcSEcCtD
Eletriptan—Body temperature increased—Methotrexate—hematologic cancer	9.68e-06	5.52e-05	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	9.66e-06	5.51e-05	CcSEcCtD
Eletriptan—Insomnia—Doxorubicin—hematologic cancer	9.59e-06	5.47e-05	CcSEcCtD
Eletriptan—Paraesthesia—Doxorubicin—hematologic cancer	9.52e-06	5.43e-05	CcSEcCtD
Eletriptan—Dyspnoea—Doxorubicin—hematologic cancer	9.45e-06	5.4e-05	CcSEcCtD
Eletriptan—Feeling abnormal—Epirubicin—hematologic cancer	9.44e-06	5.39e-05	CcSEcCtD
Eletriptan—Somnolence—Doxorubicin—hematologic cancer	9.42e-06	5.38e-05	CcSEcCtD
Eletriptan—Gastrointestinal pain—Epirubicin—hematologic cancer	9.37e-06	5.35e-05	CcSEcCtD
Eletriptan—Dyspepsia—Doxorubicin—hematologic cancer	9.33e-06	5.33e-05	CcSEcCtD
Eletriptan—ABCB1—testis—hematologic cancer	9.32e-06	0.0135	CbGeAlD
Eletriptan—Vomiting—Prednisone—hematologic cancer	9.31e-06	5.32e-05	CcSEcCtD
Eletriptan—Rash—Prednisone—hematologic cancer	9.24e-06	5.27e-05	CcSEcCtD
Eletriptan—Dermatitis—Prednisone—hematologic cancer	9.23e-06	5.27e-05	CcSEcCtD
Eletriptan—Decreased appetite—Doxorubicin—hematologic cancer	9.22e-06	5.26e-05	CcSEcCtD
Eletriptan—Headache—Prednisone—hematologic cancer	9.18e-06	5.24e-05	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Doxorubicin—hematologic cancer	9.15e-06	5.22e-05	CcSEcCtD
Eletriptan—Fatigue—Doxorubicin—hematologic cancer	9.14e-06	5.22e-05	CcSEcCtD
Eletriptan—Urticaria—Epirubicin—hematologic cancer	9.1e-06	5.2e-05	CcSEcCtD
Eletriptan—Pain—Doxorubicin—hematologic cancer	9.07e-06	5.17e-05	CcSEcCtD
Eletriptan—Constipation—Doxorubicin—hematologic cancer	9.07e-06	5.17e-05	CcSEcCtD
Eletriptan—Abdominal pain—Epirubicin—hematologic cancer	9.06e-06	5.17e-05	CcSEcCtD
Eletriptan—Body temperature increased—Epirubicin—hematologic cancer	9.06e-06	5.17e-05	CcSEcCtD
Eletriptan—Hypersensitivity—Methotrexate—hematologic cancer	9.02e-06	5.15e-05	CcSEcCtD
Eletriptan—Asthenia—Methotrexate—hematologic cancer	8.78e-06	5.01e-05	CcSEcCtD
Eletriptan—Feeling abnormal—Doxorubicin—hematologic cancer	8.74e-06	4.99e-05	CcSEcCtD
Eletriptan—Nausea—Prednisone—hematologic cancer	8.7e-06	4.97e-05	CcSEcCtD
Eletriptan—Gastrointestinal pain—Doxorubicin—hematologic cancer	8.67e-06	4.95e-05	CcSEcCtD
Eletriptan—Pruritus—Methotrexate—hematologic cancer	8.66e-06	4.94e-05	CcSEcCtD
Eletriptan—Hypersensitivity—Epirubicin—hematologic cancer	8.44e-06	4.82e-05	CcSEcCtD
Eletriptan—Urticaria—Doxorubicin—hematologic cancer	8.42e-06	4.81e-05	CcSEcCtD
Eletriptan—Body temperature increased—Doxorubicin—hematologic cancer	8.38e-06	4.78e-05	CcSEcCtD
Eletriptan—Abdominal pain—Doxorubicin—hematologic cancer	8.38e-06	4.78e-05	CcSEcCtD
Eletriptan—Diarrhoea—Methotrexate—hematologic cancer	8.38e-06	4.78e-05	CcSEcCtD
Eletriptan—Asthenia—Epirubicin—hematologic cancer	8.22e-06	4.69e-05	CcSEcCtD
Eletriptan—Pruritus—Epirubicin—hematologic cancer	8.11e-06	4.63e-05	CcSEcCtD
Eletriptan—Dizziness—Methotrexate—hematologic cancer	8.1e-06	4.62e-05	CcSEcCtD
Eletriptan—Diarrhoea—Epirubicin—hematologic cancer	7.84e-06	4.47e-05	CcSEcCtD
Eletriptan—Hypersensitivity—Doxorubicin—hematologic cancer	7.81e-06	4.46e-05	CcSEcCtD
Eletriptan—Vomiting—Methotrexate—hematologic cancer	7.78e-06	4.44e-05	CcSEcCtD
Eletriptan—Rash—Methotrexate—hematologic cancer	7.72e-06	4.41e-05	CcSEcCtD
Eletriptan—Dermatitis—Methotrexate—hematologic cancer	7.71e-06	4.4e-05	CcSEcCtD
Eletriptan—Headache—Methotrexate—hematologic cancer	7.67e-06	4.38e-05	CcSEcCtD
Eletriptan—Asthenia—Doxorubicin—hematologic cancer	7.61e-06	4.34e-05	CcSEcCtD
Eletriptan—Dizziness—Epirubicin—hematologic cancer	7.58e-06	4.32e-05	CcSEcCtD
Eletriptan—Pruritus—Doxorubicin—hematologic cancer	7.5e-06	4.28e-05	CcSEcCtD
Eletriptan—Vomiting—Epirubicin—hematologic cancer	7.28e-06	4.16e-05	CcSEcCtD
Eletriptan—Nausea—Methotrexate—hematologic cancer	7.27e-06	4.15e-05	CcSEcCtD
Eletriptan—Diarrhoea—Doxorubicin—hematologic cancer	7.25e-06	4.14e-05	CcSEcCtD
Eletriptan—Rash—Epirubicin—hematologic cancer	7.22e-06	4.12e-05	CcSEcCtD
Eletriptan—Dermatitis—Epirubicin—hematologic cancer	7.22e-06	4.12e-05	CcSEcCtD
Eletriptan—Headache—Epirubicin—hematologic cancer	7.18e-06	4.1e-05	CcSEcCtD
Eletriptan—Dizziness—Doxorubicin—hematologic cancer	7.01e-06	4e-05	CcSEcCtD
Eletriptan—Nausea—Epirubicin—hematologic cancer	6.81e-06	3.88e-05	CcSEcCtD
Eletriptan—ABCB1—lymph node—hematologic cancer	6.76e-06	0.0098	CbGeAlD
Eletriptan—Vomiting—Doxorubicin—hematologic cancer	6.74e-06	3.85e-05	CcSEcCtD
Eletriptan—Rash—Doxorubicin—hematologic cancer	6.68e-06	3.82e-05	CcSEcCtD
Eletriptan—Dermatitis—Doxorubicin—hematologic cancer	6.68e-06	3.81e-05	CcSEcCtD
Eletriptan—Headache—Doxorubicin—hematologic cancer	6.64e-06	3.79e-05	CcSEcCtD
Eletriptan—Nausea—Doxorubicin—hematologic cancer	6.3e-06	3.59e-05	CcSEcCtD
Eletriptan—Sumatriptan—ABCB1—hematologic cancer	4.31e-06	0.294	CrCbGaD
Eletriptan—HTR7—Signaling Pathways—IL2—hematologic cancer	2.32e-06	4.57e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—ALB—hematologic cancer	2.31e-06	4.56e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—TP53—hematologic cancer	2.31e-06	4.56e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CB—hematologic cancer	2.31e-06	4.55e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MTOR—hematologic cancer	2.31e-06	4.55e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—IL6—hematologic cancer	2.31e-06	4.55e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CASP3—hematologic cancer	2.31e-06	4.55e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.31e-06	4.54e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CDKN1B—hematologic cancer	2.3e-06	4.54e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL2—hematologic cancer	2.3e-06	4.54e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NUP98—hematologic cancer	2.3e-06	4.54e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—BRAF—hematologic cancer	2.3e-06	4.52e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—IL6—hematologic cancer	2.29e-06	4.52e-05	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—AKT1—hematologic cancer	2.28e-06	4.49e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCL2—hematologic cancer	2.27e-06	4.48e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL6R—hematologic cancer	2.27e-06	4.47e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CREBBP—hematologic cancer	2.26e-06	4.46e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCND1—hematologic cancer	2.26e-06	4.45e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CASP3—hematologic cancer	2.26e-06	4.45e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ABCB1—hematologic cancer	2.26e-06	4.45e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL2—hematologic cancer	2.26e-06	4.45e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—PIK3CA—hematologic cancer	2.26e-06	4.45e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—JUN—hematologic cancer	2.26e-06	4.45e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCND1—hematologic cancer	2.25e-06	4.43e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—IL6—hematologic cancer	2.24e-06	4.42e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—JUN—hematologic cancer	2.24e-06	4.42e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.23e-06	4.4e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.23e-06	4.4e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NUP214—hematologic cancer	2.22e-06	4.37e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3R1—hematologic cancer	2.21e-06	4.36e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—HRAS—hematologic cancer	2.21e-06	4.36e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.2e-06	4.34e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—HRAS—hematologic cancer	2.2e-06	4.34e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCND1—hematologic cancer	2.2e-06	4.33e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—JUN—hematologic cancer	2.19e-06	4.32e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.19e-06	4.32e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GSTM1—hematologic cancer	2.19e-06	4.32e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—NCOR1—hematologic cancer	2.19e-06	4.32e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CDKN1A—hematologic cancer	2.19e-06	4.31e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TP53—hematologic cancer	2.18e-06	4.3e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PTEN—hematologic cancer	2.18e-06	4.3e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.17e-06	4.28e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—MTR—hematologic cancer	2.17e-06	4.28e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTP1—hematologic cancer	2.17e-06	4.28e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CDKN1A—hematologic cancer	2.17e-06	4.28e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PTEN—hematologic cancer	2.17e-06	4.27e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CDKN1B—hematologic cancer	2.17e-06	4.27e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CB—hematologic cancer	2.16e-06	4.26e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAP2K1—hematologic cancer	2.16e-06	4.26e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CD—hematologic cancer	2.15e-06	4.23e-05	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—AKT1—hematologic cancer	2.14e-06	4.22e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GSTM1—hematologic cancer	2.14e-06	4.21e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—NCOR1—hematologic cancer	2.14e-06	4.21e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MAPK8—hematologic cancer	2.13e-06	4.21e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ENO2—hematologic cancer	2.13e-06	4.2e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—AKT1—hematologic cancer	2.13e-06	4.19e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CDKN1A—hematologic cancer	2.13e-06	4.19e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.13e-06	4.19e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PTEN—hematologic cancer	2.12e-06	4.18e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CASP3—hematologic cancer	2.12e-06	4.18e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MAPK8—hematologic cancer	2.12e-06	4.18e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL2—hematologic cancer	2.12e-06	4.18e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—IL6—hematologic cancer	2.12e-06	4.17e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—AKT1—hematologic cancer	2.11e-06	4.17e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—IL6—hematologic cancer	2.11e-06	4.16e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.1e-06	4.14e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—KRAS—hematologic cancer	2.1e-06	4.14e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—HRAS—hematologic cancer	2.09e-06	4.11e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EP300—hematologic cancer	2.08e-06	4.1e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MAPK8—hematologic cancer	2.08e-06	4.09e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.07e-06	4.09e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—AKT1—hematologic cancer	2.07e-06	4.08e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.07e-06	4.07e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EP300—hematologic cancer	2.07e-06	4.07e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCND1—hematologic cancer	2.07e-06	4.07e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—JUN—hematologic cancer	2.06e-06	4.06e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.06e-06	4.05e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—FGF2—hematologic cancer	2.06e-06	4.05e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CB—hematologic cancer	2.04e-06	4.03e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3R1—hematologic cancer	2.03e-06	3.99e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EP300—hematologic cancer	2.02e-06	3.99e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—SRC—hematologic cancer	2.02e-06	3.99e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—SDC1—hematologic cancer	2.02e-06	3.98e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.01e-06	3.97e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.01e-06	3.97e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—SRC—hematologic cancer	2.01e-06	3.96e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CDKN1A—hematologic cancer	2e-06	3.94e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—IL6—hematologic cancer	2e-06	3.94e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTM1—hematologic cancer	2e-06	3.94e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—NCOR1—hematologic cancer	2e-06	3.94e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PTEN—hematologic cancer	1.99e-06	3.93e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—VEGFA—hematologic cancer	1.97e-06	3.88e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—JAK2—hematologic cancer	1.97e-06	3.88e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—SRC—hematologic cancer	1.97e-06	3.88e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—VEGFA—hematologic cancer	1.96e-06	3.86e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—AKT1—hematologic cancer	1.95e-06	3.85e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—STAT3—hematologic cancer	1.95e-06	3.85e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MAPK8—hematologic cancer	1.95e-06	3.84e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NRAS—hematologic cancer	1.95e-06	3.84e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—AKT1—hematologic cancer	1.94e-06	3.83e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—STAT3—hematologic cancer	1.94e-06	3.82e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.94e-06	3.81e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NRAS—hematologic cancer	1.93e-06	3.81e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—PIK3CA—hematologic cancer	1.93e-06	3.81e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MDM2—hematologic cancer	1.92e-06	3.79e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—VEGFA—hematologic cancer	1.92e-06	3.78e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EP300—hematologic cancer	1.9e-06	3.75e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—STAT3—hematologic cancer	1.9e-06	3.74e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NRAS—hematologic cancer	1.89e-06	3.73e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—MTHFR—hematologic cancer	1.89e-06	3.72e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MTOR—hematologic cancer	1.87e-06	3.69e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CB—hematologic cancer	1.87e-06	3.69e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTEN—hematologic cancer	1.87e-06	3.68e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MAPK3—hematologic cancer	1.86e-06	3.67e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MAPK3—hematologic cancer	1.85e-06	3.65e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—SRC—hematologic cancer	1.85e-06	3.64e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—AKT1—hematologic cancer	1.84e-06	3.63e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MAPK3—hematologic cancer	1.81e-06	3.57e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MYC—hematologic cancer	1.81e-06	3.57e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TGFB1—hematologic cancer	1.81e-06	3.56e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MYC—hematologic cancer	1.8e-06	3.55e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—VEGFA—hematologic cancer	1.8e-06	3.55e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TGFB1—hematologic cancer	1.8e-06	3.54e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—HRAS—hematologic cancer	1.79e-06	3.52e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—STAT3—hematologic cancer	1.78e-06	3.51e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—EP300—hematologic cancer	1.78e-06	3.51e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.78e-06	3.51e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NRAS—hematologic cancer	1.78e-06	3.51e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTEN—hematologic cancer	1.77e-06	3.48e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.76e-06	3.48e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MYC—hematologic cancer	1.76e-06	3.48e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TGFB1—hematologic cancer	1.76e-06	3.47e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CDKN1B—hematologic cancer	1.76e-06	3.46e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—AKT1—hematologic cancer	1.74e-06	3.42e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CASP3—hematologic cancer	1.72e-06	3.39e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL2—hematologic cancer	1.72e-06	3.39e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NQO1—hematologic cancer	1.72e-06	3.39e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CD44—hematologic cancer	1.72e-06	3.39e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—IL6—hematologic cancer	1.71e-06	3.37e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.71e-06	3.36e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MAPK3—hematologic cancer	1.7e-06	3.36e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—EP300—hematologic cancer	1.68e-06	3.32e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—KRAS—hematologic cancer	1.68e-06	3.3e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCND1—hematologic cancer	1.67e-06	3.3e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—JUN—hematologic cancer	1.67e-06	3.29e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—KRAS—hematologic cancer	1.66e-06	3.28e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MYC—hematologic cancer	1.66e-06	3.27e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TGFB1—hematologic cancer	1.65e-06	3.26e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—KRAS—hematologic cancer	1.63e-06	3.21e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.63e-06	3.2e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYCS—hematologic cancer	1.63e-06	3.2e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CDKN1A—hematologic cancer	1.62e-06	3.19e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PTEN—hematologic cancer	1.62e-06	3.19e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.62e-06	3.18e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.59e-06	3.13e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	1.58e-06	3.12e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	1.58e-06	3.11e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.55e-06	3.06e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EP300—hematologic cancer	1.54e-06	3.04e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PIK3CA—hematologic cancer	1.54e-06	3.03e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—KRAS—hematologic cancer	1.53e-06	3.02e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	1.53e-06	3.01e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.51e-06	2.97e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—SRC—hematologic cancer	1.5e-06	2.95e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	1.5e-06	2.95e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.5e-06	2.95e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TP53—hematologic cancer	1.49e-06	2.93e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.48e-06	2.92e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TP53—hematologic cancer	1.48e-06	2.92e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CREBBP—hematologic cancer	1.47e-06	2.9e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	1.46e-06	2.88e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TP53—hematologic cancer	1.45e-06	2.85e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—STAT3—hematologic cancer	1.45e-06	2.85e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NRAS—hematologic cancer	1.44e-06	2.84e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.43e-06	2.82e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.43e-06	2.82e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—HRAS—hematologic cancer	1.42e-06	2.81e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—HRAS—hematologic cancer	1.41e-06	2.79e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ALB—hematologic cancer	1.41e-06	2.78e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	1.41e-06	2.77e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.4e-06	2.75e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.39e-06	2.73e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—HRAS—hematologic cancer	1.39e-06	2.73e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	1.38e-06	2.72e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ALB—hematologic cancer	1.38e-06	2.71e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.37e-06	2.71e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL6—hematologic cancer	1.36e-06	2.69e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TP53—hematologic cancer	1.36e-06	2.68e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.36e-06	2.67e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL6—hematologic cancer	1.35e-06	2.67e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.35e-06	2.66e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MYC—hematologic cancer	1.34e-06	2.65e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	1.34e-06	2.64e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL6—hematologic cancer	1.33e-06	2.61e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.32e-06	2.6e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CA—hematologic cancer	1.32e-06	2.6e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.32e-06	2.6e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.32e-06	2.6e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.31e-06	2.59e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.3e-06	2.57e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—HRAS—hematologic cancer	1.3e-06	2.56e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ALB—hematologic cancer	1.3e-06	2.56e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ALB—hematologic cancer	1.29e-06	2.54e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—AKT1—hematologic cancer	1.26e-06	2.48e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—AKT1—hematologic cancer	1.25e-06	2.46e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.25e-06	2.46e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CA—hematologic cancer	1.25e-06	2.46e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL6—hematologic cancer	1.25e-06	2.45e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.24e-06	2.45e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—KRAS—hematologic cancer	1.24e-06	2.45e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.23e-06	2.43e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—AKT1—hematologic cancer	1.22e-06	2.41e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.22e-06	2.4e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.16e-06	2.29e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—AKT1—hematologic cancer	1.15e-06	2.26e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.15e-06	2.26e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	1.14e-06	2.25e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.14e-06	2.24e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TP53—hematologic cancer	1.1e-06	2.17e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTEN—hematologic cancer	1.08e-06	2.12e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—AKT1—hematologic cancer	1.08e-06	2.12e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—HRAS—hematologic cancer	1.06e-06	2.08e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTEN—hematologic cancer	1.05e-06	2.07e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—EP300—hematologic cancer	1.03e-06	2.02e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—AKT1—hematologic cancer	1.02e-06	2.01e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.01e-06	1.99e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—EP300—hematologic cancer	1e-06	1.98e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTEN—hematologic cancer	9.9e-07	1.95e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTEN—hematologic cancer	9.82e-07	1.93e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CG—hematologic cancer	9.78e-07	1.93e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—EP300—hematologic cancer	9.44e-07	1.86e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—EP300—hematologic cancer	9.36e-07	1.85e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—AKT1—hematologic cancer	9.32e-07	1.84e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CREBBP—hematologic cancer	9.07e-07	1.79e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CD—hematologic cancer	8.6e-07	1.69e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ALB—hematologic cancer	8.49e-07	1.67e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3R1—hematologic cancer	8.12e-07	1.6e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CA—hematologic cancer	7.59e-07	1.5e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CB—hematologic cancer	7.49e-07	1.48e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CA—hematologic cancer	7.41e-07	1.46e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CA—hematologic cancer	6.99e-07	1.38e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CA—hematologic cancer	6.93e-07	1.36e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTEN—hematologic cancer	6.47e-07	1.28e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—AKT1—hematologic cancer	6.2e-07	1.22e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—EP300—hematologic cancer	6.17e-07	1.22e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—AKT1—hematologic cancer	6.06e-07	1.19e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—AKT1—hematologic cancer	5.71e-07	1.12e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—AKT1—hematologic cancer	5.66e-07	1.12e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CA—hematologic cancer	4.57e-07	9e-06	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—AKT1—hematologic cancer	3.73e-07	7.35e-06	CbGpPWpGaD
